Cross-protection against homo and heterologous influenza viruses via intranasal administration of an HA chimeric multiepitope nanoparticle vaccine.

J Nanobiotechnology · 2025 · PMC11792681 · PMID 39905416

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Additionally, the HAI titre was greater in the QIV group than in the rHA, HA-f, and HM-f groups, but this difference did not reach statistical significance (Fig. 6 a).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.